Literature DB >> 2308609

Should Jehovah's Witnesses be denied intensive chemotherapy for acute leukemia?

S L Goldberg, C S Chan, F W Dawkins, T W Mehlman, G P Schechter.   

Abstract

Entities:  

Mesh：

Year:  1990        PMID： 2308609     DOI： 10.1056/NEJM199003153221115

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  A Jehovah's Witness with Acute Myeloid Leukemia Successfully Treated with an Epigenetic Drug, Azacitidine: A Clue for Development of Anti-AML Therapy Requiring Minimum Blood Transfusions.

Authors:  Yumi Yamamoto; Akihito Kawashima; Eri Kashiwagi; Kiyoyuki Ogata
Journal:  Case Rep Hematol       Date:  2014-10-02

2.  A clinical challenge: Treatment of acute myeloid leukemia in a Jehovah's Witness.

Authors:  Daniela Cárdenas-Araujo; Elías Eugenio González-López; Xitlaly Judith González-Leal; José Carlos Jaime-Pérez; David Gómez-Almaguer
Journal:  Rev Bras Hematol Hemoter       Date:  2016-06-04

3.  Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation.

Authors:  Anand P Jillella; Martha L Arellano; Leonard T Heffner; Manila Gaddh; Amelia A Langston; Hanna J Khoury; Abhishek Mangoankar; Vamsi K Kota
Journal:  Hematol Rep       Date:  2017-09-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.